Value-added services have played a fundamental role in the growth
of the energy storage industry over the past decade and remain an
important component of new projects
BOULDER, Colo.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/EnergyStorage?src=hash” target=”_blank”gt;#EnergyStoragelt;/agt;–A new report from Navigant
Research discusses how energy storage value-added services (VASs)
have evolved and how the storage industry has grown by using VASs to
reduce customer risks.
Because potential customers are generally unfamiliar with energy storage
system (ESS) technology, VASs are required for projects to be considered
bankable by customers and investors. These services shift technological
and financial risk for project performance from customers to the battery
hardware providers and systems integrators that design and build an ESS. Click
to tweet: According to a new report from @NavigantRSRCH,
VASs present opportunities for innovative companies to establish a
leadership position as the market continues to evolve.
“VASs include operations and maintenance (O&M), warranties, and
performance guarantees, which are collectively fundamental components of
any project proposal,” says Alex Eller, senior research analyst at
Navigant Research. “Energy storage VASs have played a fundamental role
in the growth of the energy storage industry over the past decade and
will remain an important component of new projects.”
To stay competitive in this market, Navigant Research recommends ESS
providers continue to innovate on their existing VASs and maintain
flexibility in their offerings to design a VAS program to suit the needs
of their customers. Vendors of emerging technology (such as flow
batteries) need to offer VASs that can reduce the perceived risk to
customers by taking on the performance risk themselves.
The report, Energy
Storage Value-Added Services Reduce Risk and Unlock Growth Opportunities,
discusses how energy storage VASs have evolved and how the storage
industry has grown by using VASs to reduce customer risks. The study
provides an overview of the ESS project value chain including who
provides VASs and innovative approaches that companies are taking to
employ VASs in creative ways to reduce risks for customers. The report
also analyzes the potential evolution of these services, including
opportunities for new business lines and revenue streams to be developed
for both incumbents and new entrants in the market. An Executive Summary
of the report is available for free download on the Navigant
About Navigant Research
Navigant Research, the dedicated research arm of Navigant, provides
market research and benchmarking services for rapidly changing and often
highly regulated industries. In the energy sector, Navigant Research
focuses on in-depth analysis and reporting about global clean technology
markets. The team’s research methodology combines supply-side industry
analysis, end-user primary research and demand assessment, and deep
examination of technology trends to provide a comprehensive view of
clean, intelligent, mobile, and distributed energy. Additional
information about Navigant Research can be found at www.navigantresearch.com.
Navigant Consulting, Inc. is a specialized, global professional services
firm that helps clients take control of their future. Navigant’s
professionals apply deep industry knowledge, substantive technical
expertise, and an enterprising approach to help clients build, manage
and/or protect their business interests. With a focus on markets and
clients facing transformational change and significant regulatory or
legal pressures, the Firm primarily serves clients in the healthcare,
energy and financial services industries. Across a range of advisory,
consulting, outsourcing, and technology/analytics services, Navigant’s
practitioners bring sharp insight that pinpoints opportunities and
delivers powerful results. More information about Navigant can be found
* The information contained in this press release concerning the
report, Energy Storage Value-Added Services Reduce Risk and Unlock
Growth Opportunities, is a summary and reflects Navigant Research’s
current expectations based on market data and trend analysis. Market
predictions and expectations are inherently uncertain and actual results
may differ materially from those contained in this press release or the
report. Please refer to the full report for a complete understanding of
the assumptions underlying the report’s conclusions and the
methodologies used to create the report. Neither Navigant Research nor
Navigant undertakes any obligation to update any of the information
contained in this press release or the report.
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.
The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.
The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.
Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer
DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.
Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.
“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”
Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028
- Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
- Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer
- Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028
- Solei Brand Launches New Cannabis Infused Cold Brew Teas
- Proton Capital Enters Into Agreement to Purchase PharmaChoice Canada Branded Pharmacy In Saskatoon For Proposed Qualifying Transaction
- Right on Brands Announces 11th Store Opening
- HYTN Broadens Reach with Innovative Cannabis-Infused Nano Shot
- Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024
- Global Macadamia Market to Surpass USD 3.42 billion by 2031 Driven by Growing Demand for Plant-based Food Products
- Cavitation Technologies, Inc. has Renewed a 3-year Agreement With Desmet Ballestra Group s.a. and Received a $650,000 Purchase Order
- EvenMix Brings Cutting-Edge Advantage of Its Mixing Technology to Muskoka Grown
- Hemp, Inc. Profiled in Latest Global Report
- CBD Nutraceuticals Market To Reach USD 16.9 Billion By 2032 Report By DataHorizzon Research
- Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
- TILT Holding’s Jupiter Research Introduces THREDZ, the Future of 510 Cartridges
Trending on Grassnews
Cannabis2 weeks ago
Right on Brands Announces 10th Store Opening
Innocan2 weeks ago
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
Cannabis2 weeks ago
Cavitation Technologies, Inc. has Renewed a 3-year Agreement With Desmet Ballestra Group s.a. and Received a $650,000 Purchase Order
Cannabis2 weeks ago
Hemp, Inc. Profiled in Latest Global Report
Cannabis2 weeks ago
CBD Nutraceuticals Market To Reach USD 16.9 Billion By 2032 Report By DataHorizzon Research
Cannabis2 weeks ago
EvenMix Brings Cutting-Edge Advantage of Its Mixing Technology to Muskoka Grown
Cannabis2 weeks ago
TILT Holding’s Jupiter Research Introduces THREDZ, the Future of 510 Cartridges
Cannabis1 week ago
Global Macadamia Market to Surpass USD 3.42 billion by 2031 Driven by Growing Demand for Plant-based Food Products